International AIDS Society
International AIDS Society
 
 
   

Industry Liaison Forum


The Industry Liaison Forum (ILF) is an initiative of the International AIDS Society (IAS) with a mission to accelerate scientifically promising, ethical HIV research in resource-limited countries, with a particular focus on the role and responsibilities of industry as sponsors and supporters of research.


Using Antiretrovirals to Prevent HIV: Implications of the Outcome of the CAPRISA 004 Tenfovir-Gel Microbicide Trial

July 2010 


Environmental Scan: Mapping HIV Research Priorities for Women and Children

July 2010 



The International AIDS Society-Industry Liaison Forum (IAS-ILF) began the Mapping and Building Consensus on Clinical and Operations Research Priorities for Women and Children initiative in February 2009. This initiative was designed to develop a research agenda, based on the most current scientific evidence and expert advice, which would answer outstanding priority knowledge gaps in clinical and programme management relevant to the unique needs of women and children.

The Environmental Scan: Mapping HIV Research Priorities for Women and Children, which includes a comprehensive review of grey and scientific literature and key informant interviews, maps the current clinical and operations research landscape for women and children. The purpose of the environmental scan was to identify research questions required to address outstanding knowledge gaps in clinical treatment and programme delivery to these populations.

The findings of a the environmental scan were used to develop a draft set of priority clinical and operations research questions for the ILF multi-stakeholder consultation with investigators, clinicians, civil society, UN agencies and pharmaceutical and diagnostic industry, held in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa, in July 2009. The Environmental Scan provided the foundation of evidence for the consultation and subsequent recommendations released in a joint Consensus Statement, Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children, on 8 March 2010.

The Environmental Scan covers priority research questions within three broad categories: (1) clinical research on prevention of mother to child transmission (PMTCT) and paediatric treatment; (2) clinical research on treatment issues for women; and (3) operations research for women. A comprehensive review of a fourth category, operations and implementation research related to PMTCT, including paediatric care, treatment and support, has been carried out by a parallel, high-level consultation. This was led by UNICEF with the involvement of the Interagency Task Team for PMTCT, including the WHO, UNAIDS and US agencies, and carried out in collaboration with George Washington University and the Elizabeth Glaser Pediatric AIDS Foundation.

The Environmental Scan: Mapping HIV Research Priorities for Women and Children was updated to include related peer-reviewed articles and abstracts published until March 2010.

ASKING THE RIGHT QUESTIONS: Advancing an HIV Research Agenda for Women and Children

March 2010



On 8 March 2010, International Women’s Day, the International AIDS Society (IAS) and 15 other leading public and private sector organizations released a comprehensive research agenda designed to significantly advance global responses to HIV in women, girls and children. The new consensus statement, Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children, includes 20 specific recommendations to expand and improve responses to the HIV-related challenges facing women and children worldwide.

The Agenda identifies priority research questions within four broad categories: 1) clinical research on prevention of mother-to-child transmission (PMTCT) and paediatric treatment; 2) clinical research on treatment issues for women; 3) operations research for women; and 4) operations and implementation research related to PMTCT, including paediatric care, treatment and support. Recommendations in the fourth category of the agenda were developed through a parallel, high level consultation led by UNICEF, with the involvement of the Interagency Task Team for PMTCT, including the WHO, UNAIDS and US agencies and in collaboration with George Washington University (GWU) and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). Information on the UNICEF-led initiative, including the final list of operations/implementation research recommendations for PMTCT and paediatric care, treatment and support from a September 2009 expert consultation held in Washington, will be available online at www.unicef.org or www.pedaids.org.


Read the related press release here 





To see a webcast of the multi-stakeholder consultation held in July 2009, click here







To download the full consensus statement – ASKING THE RIGHT QUESTIONS: Advancing an HIV Research Agenda for Women and Children, click here





Read recent ILF reports:

 
HIV/Pharma News

16 July 2010
ViiV Healthcare announces further initiatives to improve access to HIV medications for people living in the least developed countries

17 June 2010
ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia

7 June 2010
UNITAID Response to Bristol Myers Squibb Interrupted Production of HIV Medicines for Infants

7 June 2010
ViiV Healthcare and Elizabeth Glaser Pediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children

4 March 2010
Women ARISE – A new global coalition focused on women, girls and HIV – launches and calls on governments and UN to take action on UNAIDS agenda for women and girls

2 March 2010
UNAIDS takes action to empower women and girls to protect themselves from HIV

20 January 2010
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries

30 November 2009
Children and AIDS: Innovations in HIV treatment, prevention and care

30 November 2009
Data shows progress needed on HIV testing and treatment for children and mothers 

03 November 2009
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care; CEO promises ‘relentless pursuit’ of new treatments

21 September 2009
Wellcome Trust and Merck Launch First of its Kind Joint Venture to Develop Affordable Vaccines for Low-income Countries

4 September 2009
The perils of success: what if the new HIV prevention methods work?

7 August 2009
Clinton Foundation Reaches Deal With Matrix, Pfizer to Cut Prices for Second-Line ARVs, TB Drug

16 April 2009
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company

8 December 2008
CME/CE-Certified Expert Analysis From IAC 2008: HIV Management and Women
Discussion by Kathleen E. Squires, MD, Judith S. Currier, MD, MSc, and Sally Hodder, MD

10 October 2008
Major drug firms including Abbott, Boehringer Ingelheim, Glaxo, Pfizer, agree with Ban Ki-Moon to invest more in AIDS treatments & diagnostics for poor regions

2009 Sponsoring Industry Partners


 
Boehringer Ingelheim
 
Gilead
 
 
 
Pfizer Global Pharmaceuticals
 
Gilead